增强型体外反搏治疗冠心病不稳定型心绞痛患者的临床疗效观察  

Clinical Efficacy of Enhanced External Counterpulsation on Unstable Angina Pectoris of Coronary Heart Disease

作　　者：徐春华[1] 何军[1] 张平[1] 霍雨佳 赵琼华 XU Chunhua;HE Jun;ZHANG Ping;HUO Yujia;ZHAO Qionghua(Department of Cardiology,Neijiang Second People's Hospital,Neijiang 641100,Sichuan,China;Department of Cardiology,Baoji People'sHospital,Baoji721000,Shaanxi,China)

机构地区：[1]内江市第二人民医院心血管内科,内江市641100 [2]宝鸡市人民医院心血管内科,宝鸡市721000

出　　处：《中国分子心脏病学杂志》2022年第4期4815-4819,共5页Molecular Cardiology of China

基　　金：四川省医学会课题(S19043)。

摘　　要：目的探讨增强型体外反搏治疗冠心病不稳定型心绞痛的临床疗效。方法收集2018年5月至2020年5月收治的92例冠心病不稳定型心绞痛患者的临床资料。根据治疗方法将患者分为对照组(常规治疗,n=45)和研究组(增强型体外反搏治疗,n=47)。对比两组临床疗效、绞痛持续时间、硝酸甘油用量、实验室指标[前列环素(PGI_(2))、组织型纤溶酶原激活物(t-PA)、血管紧张素Ⅱ(AngⅡ)、血栓素B(TXB_(2))]、不良反应。结果研究组临床总有效率(91.49%)显著高于对照组(75.56%),两组比较存在明显差异(P<0.05)。与治疗前比较,两组治疗后心绞痛持续时间、硝酸甘油用量均减少,其中以研究组最为显著,比较差异具有统计学意义(P<0.05);与治疗前比较,研究组治疗后PGI_(2)、t-PA上升,AngⅡ、TXB_(2)下降,且研究组治疗后PGI_(2)和t-PA高于对照组、AngⅡ和TXB_(2)低于对照组(P<0.05)。研究组不良反应发生率为14.89%,对照组为8.89%,两组比较无显著差异(P>0.05)。结论增强型体外反搏治疗冠心病不稳定型心绞痛疗效确切,可在降低心绞痛持续时间的同时减少硝酸甘油用量,改善PGI_(2)、t-PA、AngⅡ、TXB_(2)水平,且安全性高,值得临床推广应用。Objective To investigate the clinical effect of enhanced external counterpulsation in the treatment of patients with unstable angina pectoris of coronary heart disease.Methods The clinical data of 92 patients with unstable angina pectoris admitted to our hospital from May 2018 to May 2020 were collected.According to the treatment method,the patients were divided into a control group(conventional treatment,n=45)and a study group(enhanced external counterpulsation therapy,n=47).The clinical efficacy,duration of angina pectoris,dosage of nitroglycerin,laboratory indicators[prostacyclin(PGI_(2)),tissue-type plasminogenactivator(t-PA),angiotensinⅡ(AngⅡ),thromboxane B(TXB_(2))],adverse reactions were compared between the two groups.Results The total clinical effective rate of the study group(91.49%)was significantly higher than that of the control group(75.56%),there was a significant difference between the two groups(P<0.05).Compared with each group,the duration of angina pectoris and the dosage of nitroglycerin were reduced after treatment.Among them,the study group was the most significant,and the difference was statistically significant(P<0.05);Compared with before treatment,PGI_(2)and t-PA after treatment in the study group increased,AngⅡ,TXB_(2)decreased,and PGI_(2)2 and t-PA of the study group were higher than that of the control group,AngⅡ,TXB_(2)were lower than that of the control group after treatment(P<0.05).The incidence of adverse reactions in the study group was 14.89%,the control group was8.89%,there was no difference between the two groups(P>0.05).Conclusion Enhanced external counterpulsation is effective in the treatment of unstable angina pectoris of coronary heart disease,it can reduce the duration of angina pectoris and reduce the dosage of nitroglycerin,improve PGI_(2),t-PA,AngⅡ,TXB_(2)levels,and has high safety,which is worthy of clinical application.

关 键 词：增强型体外反搏 前列环素 冠心病不稳定型心绞痛 血管紧张素Ⅱ 血栓素B2 

分 类 号：R541.4[医药卫生—心血管疾病]